Compare Alphabet Inc Class A (GOOGL) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Novavax Inc — how do they compare? Alphabet Inc Class A trades at $351.66 (market cap $4.24T), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Alphabet Inc Class A is far larger — about 2329.7× Novavax Inc's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and Novavax Inc for 59 Days on average.
| GOOGL | NVAX | |
|---|---|---|
Market Cap | $4.24T | $1.82B |
Volume | 23,392,850 | 6,198,505 |
Sector | Media | Health |
52-Week High | $402.62 | $12.56 |
52-Week Low | $236.59 | $6.22 |
Typical Hold Time | 85 Days | 59 Days |
Enterprise Value | $4.13T | $1.39B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $348.29, down 0.63% on the day, amid strong fundamental performance with Q2 2026 EPS beating expectations by 217%. The stock shows bullish technical signals with moving averages supporting upward momentum, while maintaining robust profitability metrics including 54.77% net income margin and 49.55% ROE. Recent developments include YouTube subscription price increases and AI infrastructure partnerships driving growth prospects.
With 87% analyst buy ratings and a $431.83 consensus target representing 24% upside, GOOGL presents compelling value at current levels. Key risks include antitrust scrutiny and AI competition, but strong cash flow generation and consistent earnings beats support long-term growth trajectory. The company's diversified revenue streams and AI leadership position it well for sustained outperformance.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
